Omeros announced that the company submitted a New Drug Application (NDA) to the FDA for approval of OMS302 for use in patients undergoing intraocular lens replacement (ILR) surgery.

OMS302, added to standard irrigation solution used during ILR, demonstrated clinically meaningful and statistically significant maintenance of intraoperative mydriasis (pupil dilation), prevention of intraoperative miosis (pupil constriction), and reduction of postoperative ocular pain across multiple human trials.

OMS302 is a combination of ketorolac, an anti-inflammatory agent, and phenylephrine, a mydriatic (pupil dilating) agent.

For more information call (206) 676-5005 or visit www.omeros.com.